Home>Topics>Companies>Regeneron Pharmaceuticals

Regeneron Pharmaceuticals

  1. All
  2. Commentary
  3. Video Reports
  4. Headlines
  1. UPDATE 2- Regeneron expects Eylea sales to grow faster than expected

    Headlines

    Thu, 7 May 2015

    May 7 (Reuters) - Regeneron Pharmaceuticals Inc said it expects sales of blockbuster eye drug Eylea to grow even more quickly following data that showed it was superior to rival treatments.

  2. Regeneron Reports Strong 1Q as Eylea Growth Benefits from DME Indication; Increasing FVE

    Commentary

    Thu, 7 May 2015

    We plan to increase Regeneron ’s fair value estimate of $415 by ..... strong results were driven by U.S. Eylea sales and updated 2015 guidance of ..... first quarter of 2014. Revenue included Eylea U.S. sales of $541 million, up ..... driven by new DME patients. Ex-U.S. Eylea sales, as reported by partner Bayer ..... rheumatoid arthritis later this year and Regeneron plans on filing for approval by year-end

  3. REFILE- Regeneron profit rises as Eylea sales jump

    Headlines

    Thu, 7 May 2015

    May 7 (Reuters) - Regeneron Pharmaceuticals Inc reported an 11 percent rise in quarterly profit, driven by surging demand for its top-selling eye drug, Eylea .

  4. Global Diabetic Retinopathy Market 2015 - Global Market Size, Trends, Development, and Forecasts to 2019

    Commentary

    Tue, 21 Apr 2015

    Americas - EMEA - APAC Key Vendors - Bayer AG - F. Hoffmann-La Roche Ltd. - Novartis AG - Pfizer Inc. - Regeneron Pharmaceuticals Inc . - Valeant Pharmaceuticals International Inc. Other Prominent Vendors - Abbott Laboratories Ltd. - Alcon

  5. Actavis' Wide-Moat Transformation Offers Shareholder Rewards

    Headlines

    Mon, 23 Mar 2015

    anti-VEGF treatments that require monthly injections (Roche's RHHBY Lucentis) and bimonthly injections ( Regeneron 's REGN Eylea ). We think the first DARPin molecule is likely to enter Phase III trials by 2016. Molecular Partners can earn

  6. Complexities of Eye Care Drive Strong Moats

    Headlines

    Fri, 6 Mar 2015

    degeneration have been wildly successful, with Regeneron 's REGN and Bayer 's BAYRY Eylea and Novartis ' NVS and Roche 's RHHBY ..... We are relatively enthusiastic about Regeneron , as we expect Eylea 's dosing advantage and the addition of

  7. Regeneron Reports Solid 4Q, Gives Stronger-Than-Expected Eylea Guidance; Increasing Fair Value

    Commentary

    Tue, 10 Feb 2015

    increasing our fair value estimate for Regeneron to $383 per share from $365 following ..... of better-than-anticipated U.S. Eylea sales guidance of $2.17 billion ..... fourth quarter of 2013. Revenue included Eylea U.S. sales of $518 million, up 29 ..... that indication last year. Ex-U.S. Eylea sales, as reported by partner Bayer

  8. A Biotech With a Growing Moat

    Video Reports

    Wed, 31 Dec 2014

    Stefan Quenneville: Regeneron ( REGN ) is a biotechnology company ..... largely due to its key drug Eylea , which is a growing blockbuster ..... of biotechs fail here. But Regeneron has been able to do this successfully ..... really what's driving [ Regeneron 's] positive moat trend

    REGN found at 0:03

    Stefan Quenneville: Regeneron ( REGN ) is a biotechnology company that we rate as having a narrow moat and a positive moat trend. We think its positive moat trend is driven by its recent string of clinical and commercial successes, as well as its very full and productive drug-development pipeline. The company turned profitable in 2012, largely due to its key drug Eylea , which is a growing blockbuster that treats degenerative eye diseases. What's really important, though, from a moat perspective is the company's ability to reinvest those profits to develop new drugs that target attractive market opportunities. This is a very challenging thing to do for a lot of biotechs; a lot of biotechs fail here. But Regeneron has been able to do this successfully, and we really think this is what's driving its long-term competitive advantage, or its moat. Currently, the company has 16 drugs in clinical development, including three very promising drugs in Phase III. We think each of those Phase III drugs has the opportunity to be a blockbuster in its own right. So overall, this strong R&D productivity, as well as this progress in its pipeline, is really what's driving [ Regeneron's ] positive moat trend. Currently, the company is trading at a slight premium to our fair value of $365 per share, but we
  9. Regeneron Reports Soft Q3 Eylea Sales and Guidance; Maintaining Fair Value Estimate

    Commentary

    Tue, 4 Nov 2014

    maintaining our $365 fair value estimate for Regeneron after third-quarter results that were below expectations, with U.S. Eylea sales growing less than expected and ..... diabetic macular edema (DME) would allow Eylea sales to accelerate more rapidly into ..... recent superior top-line results of Eylea versus Lucentis and Avastin in a National

  10. Positive DME Trial Results Trump PCSK9 Patent Lawsuit; Slightly Raising FVE

    Commentary

    Fri, 17 Oct 2014

    We are slightly raising Regeneron 's FVE to $365 per share (from ..... macular edema, which showed that Eylea demonstrated better efficacy and safety ..... patent infringement lawsuit against Regeneron /Sanofi’s PCSK9 drug, Alirocumab

« Prev12345Next »
Content Partners